You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The Broad Institute's lawyers used statements from Jennifer Doudna to undermine UC's case that one could expect CRISPR/Cas9 to work in eukaryotic cells.
The platform, called Seq-Well, is similar to droplet-based approaches but reports increased efficiency.
MIT President Rafael Reif speaks with the Los Angeles Times about the Trump administration travel ban and more.
In Cell this week: strategies for targeting leukemia with MLL translocations, new Perturb-seq approach, and more.
The licenses cover IP related to a new CRISPR technology known as Cpf1, advanced forms of Cas9, and additional Cas9-based genome editing technologies.
Two Broad Institute teams, led by Eric Lander and Feng Zhang, respectively, have published new papers today in Science on new uses for lenti-CRISPR screens.
Researchers are making mutations in a cell's genome to mark it and later read out that information to create cell lineage maps and chemical interaction histories.
The method works by adding noise to database search results to confound algorithms that try to access private details about contributing individuals.
The Food Allergy Science Initiative seeks to supply the basic scientific research needed to spur future development of diagnostics and therapeutics.
Discovered and characterized through a collaboration between Feng Zhang's lab and the NCBI, C2c2 opens up the RNA world to editing and other applications.
Retraction Watch writes that a cancer researcher has had an eighth paper retracted.
Computational biologist James Taylor has died, according to Johns Hopkins University.
The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.
In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.